Dose Response and Dose Equivalence of Antipsychotics

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Psychopharmacology

• Publication date

  2004-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/01.jcp.0000117422.05703.aePMID 15206667
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Aripiprazole in the treatment of schizophrenia].

  2005cited by this paper
• Clinical response and plasma haloperidol levels in schizophrenia

  2004cited by this paper
• High dosage haloperidol therapy in chronic schizophrenic patients: A double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin

  2004cited by this paper
• Prophylactic effect of neuroleptics in symptom-free schizophrenics

  2004cited by this paper
• Chlorpromazine in chronic schizophrenia: Behavioral dose-response relationships

  2004cited by this paper
• Differential improvements from haloperidol in two types of schizophrenics

  2004cited by this paper
• Prophylactic effect of neuroleptics in symptom-free schizophrenics: A comparative dose-response study of haloperidol and propericiazine

  2004cited by this paper
• Clinical Handbook of Psychotropic Drugs. 12th Revised Edition

  2003cited by this paper
• Antipsychotic dosage at hospital discharge and outcomes among persons with schizophrenia.

  2003cited by this paper
• Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder

  2003cited by this paper
• Effectiveness of Rapid Initial Dose Escalation of up to Forty Milligrams per Day of Oral Olanzapine in Acute Agitation

  2003cited by this paper
• Patterns of Antipsychotic and Anticholinergic Prescribing for Hospital Inpatients

  2003cited by this paper
• The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

  2003cited by this paper
• The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders.

  2003cited by this paper
• A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.

  2002cited by this paper
• Optimal Dosing of Atypical Antipsychotics in Adults: A Review of the Current Evidence

  2002cited by this paper
• A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

  2002cited by this paper
• Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.

  2002cited by this paper
• Clinical profile of an atypical antipsychotic: risperidone.

  2002cited by this paper
• Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

  2002cited by this paper
• Is the Time Course of Clozapine Response Correlated to the Time Course of Clozapine Plasma Levels? A One-Year Prospective Study in Drug-Resistant Patients with Schizophrenia

  2002cited by this paper
• Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

  2002cited by this paper
• Antipsychotic dosing and concurrent psychotropic treatments for Medicaid-insured individuals with schizophrenia.

  2002cited by this paper
• A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.

  2002cited by this paper
• Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.

  2001cited by this paper
• The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials.

  2001cited by this paper
• Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

  2001cited by this paper
• Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics

  2000cited by this paper
• Risperidone versus typical antipsychotic medication for schizophrenia

  2000cited by this paper
• Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

  2000cited by this paper
• High-dose treatment with haloperidol: the effect of dose reduction.

  2000cited by this paper
• Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses?

  2000cited by this paper
• Risperidone versus typical antipsychotic medication for schizophrenia.

  2000cited by this paper
• Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

  2000cited by this paper
• Treatment of schizophrenia 1999. The expert consensus guideline series.

  1999cited by this paper
• Expert Consensus Guideline Series Treatment of Schizophrenia 1999

  1999cited by this paper
• Consultant for the Pharmacotherapy of Schizophrenia

  1999cited by this paper
• Double-blind study of clozapine dose response in chronic schizophrenia.

  1999cited by this paper
• The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms.

  1999cited by this paper
• Treatment of schizophrenia 1999

  1999cited by this paper
• Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement

  1999cited by this paper
• Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.

  1999cited by this paper
• Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.

  1999cited by this paper
• Haloperidol plasma levels and dose optimization.

  1998cited by this paper
• Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

  1998cited by this paper
• Canadian Clinical Practice Guidelines for the Treatment of Schizophrenia

  1998cited by this paper
• A new algorithm for treating schizophrenia.

  1998cited by this paper
• Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group.

  1998cited by this paper
• Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose‐ranging study vs. haloperidol

  1998cited by this paper
• Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association.

  1997cited by this paper
• Practice guideline for the treatment of patients with schizophrenia

  1997cited by this paper
• Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.

  1997cited by this paper
• The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

  1997cited by this paper
• Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.

  1997cited by this paper
• The Dose Reduction in Schizophrenia (DORIS) Study: a final report.

  1997cited by this paper
• Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

  1997cited by this paper
• Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.

  1997cited by this paper
• A two‐phase, double‐blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non‐responders

  1997cited by this paper
• Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

  1997cited by this paper
• Safety and efficacy of once-daily risperidone in the treatment of schizophrenia

  1997cited by this paper
• P.2.114 Aripiprazole, a new typical antipsychotic: Phase 2 clinical trial result

  1997cited by this paper
• Clinical Handbook of Psychotropic Drugs

  1997cited by this paper
• MetaWin: Statistical Software for Meta-analysis with Resampling Tests

  1997cited by this paper
• Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

  1996cited by this paper
• Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges.

  1996cited by this paper
• Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients.

  1996cited by this paper
• Guidelines for ATC classification and DDD assignment

  1996cited by this paper
• A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

  1996cited by this paper
• Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol

  1995cited by this paper
• Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

  1995cited by this paper
• Further evidence of a dose-response threshold for haloperidol in psychosis.

  1995cited by this paper
• P-4-71 Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patients

  1995cited by this paper
• Fluphenazine plasma levels, dosage, efficacy, and side effects.

  1995cited by this paper
• Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder.

  1995cited by this paper
• Plasma clozapine concentrations as a predictor of clinical response: a follow-up study.

  1994cited by this paper
• Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.

  1994cited by this paper
• Haloperidol: therapeutic window in schizophrenia.

  1994cited by this paper
• Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials

  1994cited by this paper
• A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

  1993cited by this paper
• Treatment of neuroleptic-resistant schizophrenic relapse.

  1993cited by this paper
• Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking.

  1993cited by this paper
• A dose-finding study with remoxipride in the acute treatment of schizophrenic patients.

  1992cited by this paper
• Haloperidol blood levels and clinical effects.

  1992cited by this paper
• Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.

  1992cited by this paper
• [Drug treatment of schizophrenic patients].

  1991cited by this paper
• Dosage of haloperidol for schizophrenia.

  1991cited by this paper
• Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

  1991cited by this paper
• Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients.

  1991cited by this paper
• Pyramidical model of schizophrenia.

  1990cited by this paper
• A double‐blind multicentre comparison of remoxipride, at two dose levels, and haloperidol

  1990cited by this paper
• Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.

  1990cited by this paper
• Haloperidol Plasma Level after a Test Dose as Predictor for the Clinical Response to Treatment in Acute Schizophrenic Patients

  1988cited by this paper
• Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

  1988cited by this paper
• Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.

  1988cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• Clinical effectiveness of oral and parenteral rapid neuroleptization.

  1987cited by this paper
• Treatment-resistant schizophrenia: controlled study of moderate- and high-dose thiothixene.

  1987cited by this paper
• A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function.

  1987cited by this paper
• [Comparison of the therapeutic effects between haloperidol and insulin coma in schizophrenia and optimal blood levels of haloperidol].

  1987cited by this paper
• Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.

  1987cited by this paper

• Alterations of structural-functional coupling in bipolar disorder patients with suicidal ideation correlated with chronotype.

  2025cites this paper
• Patient and clinician perspectives on pharmacogenetic testing for antipsychotics

  2025cites this paper
• Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence

  2025cites this paper
• Anhedonia relates to reduced striatal reward anticipation in depression but not in schizophrenia or bipolar disorder: A transdiagnostic study

  2025cites this paper
• Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics

  2025cites this paper
• Unraveling antipsychotic induced weight gain in schizophrenia - A proof-of-concept study exploring the impact of the cumulative historical occupancy of different receptors by antipsychotics.

  2025cites this paper
• Associations between polygenic risk for anhedonia and functional brain activity during reward processing.

  2025cites this paper
• Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application.

  2024cites this paper
• Abnormal activation patterns in MT+ during visual motion perception in major depressive disorder

  2024cites this paper
• Motor versus Psychomotor? Deciphering the Neural Source of Psychomotor Retardation in Depression

  2024cites this paper
• Evaluation of the pharmacodynamic interaction effect of augmentation agents with clozapine in patients with treatment-resistant schizophrenia: A simulation study of clinical data.

  2024cites this paper
• Valsartan as a prophylactic treatment against breast cancer development and niche activation: What molecular sequels follow chronic AT-1R blockade?

  2024cites this paper
• From periphery immunity to central domain through clinical interview as a new insight on schizophrenia

  2024cites this paper
• Nicotine-related beliefs induce dose-dependent responses in the human brain

  2024cites this paper
• Irregularity of visual motion perception and negative symptoms in schizophrenia

  2024cites this paper
• Guideline for pharmacological treatment of schizophrenia 2022

  2024cites this paper
• Comparative modeling of fetal exposure to maternal long-acting injectable versus oral daily antipsychotics

  2024cites this paper
• Shared and distinct patterns of dynamic functional connectivity variability of thalamo-cortical circuit in bipolar depression and major depressive disorder.

  2023cites this paper
• Brain‐derived subgroups of bipolar II depression associate with inflammation and choroid plexus morphology

  2023cites this paper
• Patterns of psychotropic drug use in veterans with epilepsy: Do drug interactions matter?

  2023cites this paper
• Second International Consensus Study of Antipsychotic Dosing (ICSAD-2)

  2023cites this paper
• Reward and punishment learning deficits among bipolar disorder subtypes.

  2023cites this paper
• Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis

  2023cites this paper
• Comparison of clozapine doses and tolerability in patients with and without concurrent valproic acid

  2022cites this paper
• Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”

  2022cites this paper
• Polypharmacy- Purpose, Benefits and Limitations.

  2022cites this paper
• Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study

  2022cites this paper
• Use of Olanzapine to Treat Agitation in Traumatic Brain Injury: A Series of N-of-One Trials

  2022cites this paper
• Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital

  2022cites this paper
• Response to Comment on “An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”

  2022cites this paper
• “Skills for pills”: The dialectical‐behavioural therapy skills training reduces polypharmacy in borderline personality disorder

  2022cites this paper
• Choosing an Optimal Antipsychotic Dose for Relapse Prevention

  2022cites this paper
• Views of Patients and Healthcare Providers on Pharmacogenetic Screening for Antipsychotic Medications

  2021cites this paper
• From Molecular to Behavior: Higher Order Occipital Cortex in Major Depressive Disorder.

  2021cites this paper
• Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”

  2021cites this paper
• Ventral Striatal-Hippocampus Coupling During Reward Processing as a Stratification Biomarker for Psychotic Disorders.

  2021cites this paper
• Prefrontal-limbic-striatum dysconnectivity associated with negative emotional endophenotypes in bipolar disorder during depressive episodes.

  2021cites this paper
• Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms.

  2021cites this paper
• Examining long-acting injectable antipsychotic (depot) medication in the elderly: a five-year retrospective cross-sectional study evaluating depot use in an Australian psychogeriatric service

  2021cites this paper
• Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients

  2021influential citation
• Schizophrenia and Related Psychoses

  2021cites this paper
• A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia

  2021cites this paper
• Antipsychotic drug dose in real-life settings results from a Nationwide Cohort Study

  2021cites this paper
• Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence

  2021cites this paper
• Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA)

  2020cites this paper
• The effect of neuroleptic drugs on DPPC/sphingomyelin/cholesterol membranes.

  2020cites this paper
• Frequency-specific alteration of functional connectivity density in bipolar disorder depression.

  2020cites this paper
• Default mode network subsystem alterations in bipolar disorder during major depressive episode.

  2020cites this paper
• Perspective on medication decisions following remission from first-episode psychosis.

  2020cites this paper
• Relative Stability of Alexithymia and Openness to Emotions in one Psychiatric Day Hospital Setting.

  2020cites this paper
• High-dose antipsychotic therapy and reflective prescribing: development of an online tool for rapid, easy calculation of antipsychotic total daily dose

  2020cites this paper
• Pharmakotherapie der therapieresistenten Schizophrenie

  2019cites this paper
• Altered resting‐state cerebral blood flow and functional connectivity of striatum in bipolar disorder and major depressive disorder

  2019influential citation
• Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.

  2019cites this paper
• Liječenje rezistentne shizofrenije

  2019cites this paper
• ESQUIZOFRENIA

  2019cites this paper
• Evidence for using PRN Pharmacotherapy to Treat Undifferentiated Acute Agitation or Aggression

  2019cites this paper
• Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT.

  2019cites this paper
• Antipsychotic drugs v. barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis

  2019cites this paper
• Dysfunctional connectivity between raphe nucleus and subcortical regions presented opposite differences in bipolar disorder and major depressive disorder

  2019influential citation
• Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia—a systematic review of the literature

  2019cites this paper
• The role of premorbid adjustment in schizophrenia: Focus on cognitive remediation outcome

  2019cites this paper
• Tractography‐based classification in distinguishing patients with first‐episode schizophrenia from healthy individuals

  2019cites this paper
• Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

  2019influential citation
• Why maximum tolerated dose?

  2019cites this paper
• Age-related deficits in intracortical myelination in young adults with bipolar disorder type I

  2019cites this paper
• The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder.

  2019cites this paper
• Sleep and Parasympathetic Activity during Rest and Stress in Healthy Adolescents and Adolescents with Bipolar Disorder.

  2019cites this paper
• Transdiagnostic and diagnosis‐specific dynamic functional connectivity anchored in the right anterior insula in major depressive disorder and bipolar depression

  2018influential citation
• The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses

  2018cites this paper
• Structural and functional changes in the somatosensory cortex in euthymic females with bipolar disorder

  2018cites this paper
• Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis

  2018cites this paper
• Social stress response in adolescents with bipolar disorder.

  2018cites this paper
• Source flexibility in schizophrenia: specificity and role in auditory hallucinations

  2018cites this paper
• Brain Structure and Function in Women with Comorbid Bipolar and Premenstrual Dysphoric Disorder

  2018cites this paper
• Treatment-Resistant Schizophrenia: Assessment and Management

  2018cites this paper
• Title Dose equivalents of antidepressants : Evidence-based recommendations from randomized controlled trials

  2018cites this paper
• Antipsychotics prescribing and ethnicity

  2018cites this paper
• Achieving recovery in patients with schizophrenia through psychosocial interventions: A retrospective study

  2018cites this paper
• The cognitive and behavioural consequences of psychotic experiences

  2017cites this paper
• Is Longer Treatment Better? A Comparison Study of 3 Versus 6 Months Cognitive Remediation in Schizophrenia

  2017influential citation
• Antipsychotic prescribing and rehospitalisation in schizophrenia: A New Zealand study

  2017cites this paper
• Pharmacovigilance of Neuroleptics and Benzodiazepines in the Psychiatric Teaching Hospital of Benin Republic

  2017cites this paper
• Cognitive Remediation and Functional Improvement in Schizophrenia: is it a Matter of Size?

  2017cites this paper
• Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method.

  2017cites this paper
• Resting state functional connectivity in women with bipolar disorder during clinical remission

  2017cites this paper
• Multidimensional cognitive impairment in unipolar and bipolar depression and the moderator effect of adverse childhood experiences

  2017cites this paper
• Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing

  2017cites this paper
• Distribution and levels of 5-HT1B receptors in anterior cingulate cortex of patients with bipolar disorder, major depressive disorder and schizophrenia - An autoradiography study.

  2017cites this paper
• Integrated cognitive remediation and standard rehabilitation therapy in patients of schizophrenia: persistence after 5years.

  2017cites this paper
• Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points

  2017cites this paper
• Equivalent linear change in cognition between individuals with bipolar disorder and healthy controls over 5 years

  2017cites this paper
• Influence of cognitive reserve on neuropsychological functioning in bipolar disorder: Findings from a 5‐year longitudinal study

  2017cites this paper
• You'll feel better in the morning: slow wave activity and overnight mood regulation in interepisode bipolar disorder

  2017cites this paper
• Figures Title : You ’ ll feel better in the morning : Slow wave activity and overnight mood regulation in interepisode bipolar disorder

  2017cites this paper
• Facial emotion recognition and alexithymia in Chinese male patients with deficit schizophrenia.

  2016cites this paper
• Neurocognitive functions in schizophrenia: A systematic review of the effects of typical and atypical antipsychotic drugs.

  2016cites this paper
• Similar Trajectory of Executive Functioning Performance over 5 years among individuals with Bipolar Disorder and Unaffected Controls using Latent Growth Modeling.

  2016cites this paper
• Contrasting variability patterns in the default mode and sensorimotor networks balance in bipolar depression and mania

  2016cites this paper
• Do doctors agree on doses of antipsychotic medications?

  2016cites this paper